Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04605588 · ClinicalTrials.gov registry record · Phase 2
A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19
A Phase 2 study, sponsored by Rutgers, The State University of New Jersey.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT04605588 is a Phase 2 study that was terminated before completion, run by Rutgers, The State University of New Jersey. The registered enrollment target is 7 participants.
The verdict
NCT04605588, a Phase 2 study, was terminated before completion, sponsored by Rutgers, The State University of New Jersey.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
New outpatient treatments for COVID-19 are urgently needed. There is some evidence that a combination of three medications currently used to treat other viral infections could be effective in fighting this new virus. The purpose of this trial is to evaluate the efficacy of Nitazoxanide (NTZ), Ribavirin (RBV) and Hydroxychloroquine (HCQ) versus placebo in participants with proven SARS-CoV-2 infection The study will enroll 70 participants within the 7 days after having been diagnosed with coronavirus infection. The purpose is to determine if those randomized to 5-day dosing with the three medication combination have decreased viral load and severity of illness in the 10 days following treatment as compared to those taking placebo. Participants will be actively followed for 28 days.
Interventions
- DRUG Hydroxychloroquine
- DRUG Ribavirin
- DRUG Nitazoxanide
- DRUG Placebo Nitazoxanide
- DRUG Placebo Ribavirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2020-12-02 |
| Est. Completion | 2021-02-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04605588
The ClinicalTrials.gov registry entry for NCT04605588 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Hydroxychloroquine is the first listed.
NCT04605588 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04605588 about?
NCT04605588 is a clinical study titled "A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19". New outpatient treatments for COVID-19 are urgently needed. There is some evidence that a combination of three medications currently used to treat other viral infections could be effective in fighting this new virus. The purpose of this trial is to evaluate the efficacy of Nitazoxanide (NTZ), Ribavi...
What is the current status of trial NCT04605588?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2020-12-02. Estimated completion is 2021-02-04.
What interventions are being tested in trial NCT04605588?
The interventions under investigation include: Hydroxychloroquine (DRUG), Ribavirin (DRUG), Nitazoxanide (DRUG), Placebo Nitazoxanide (DRUG), Placebo Ribavirin (DRUG).
Who is sponsoring clinical trial NCT04605588?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.